CN106420658A - Ceftazidime capsule for treating surgical infection - Google Patents
Ceftazidime capsule for treating surgical infection Download PDFInfo
- Publication number
- CN106420658A CN106420658A CN201610845670.2A CN201610845670A CN106420658A CN 106420658 A CN106420658 A CN 106420658A CN 201610845670 A CN201610845670 A CN 201610845670A CN 106420658 A CN106420658 A CN 106420658A
- Authority
- CN
- China
- Prior art keywords
- ceftazidime
- capsule
- cross
- weight
- silica gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
- C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines, and discloses a ceftazidime capsule for treating surgical infection. A structural formula of a ceftazidime crystal compound is as shown in a formula (I), the crystal compound is measured by a powder X-ray diffraction measurement method, and an X-ray powder diffraction spectrum shown by a diffraction angle of 2 theta +/- 0.2 degrees is as shown in a figure 1. The capsule prepared from the crystal compound is high in dissolution rate, low in impurity content and good in stability.
Description
Technical field
The invention belongs to pharmaceutical technology field is and in particular to a kind of medicine ceftazidime glue treating Postoperative infection
Capsule.
Background technology
Ceftazidime pentahydrate is anti Bacillus pyocyaneu Flugge effect in the third generation cephalosporin that GlaxoSmithKline PLC company is formulated
Antibiotic the strongest, for the septicemia caused by sensitive gram negative bacilli, lower respiratory infection, abdominal cavity and biliary tract infection, again
Polygamy urinary tract infection and serious skin soft tissue infection etc..For the immunodeficiency person being caused by multiple drug resistance gram negative bacillis
Caused by infection, nosocomial infection and gram negative bacilli or Pseudomonas aeruginosa, central nervous system infection is especially suitable.Its
Structural formula is：
.
In order to ensure human administration's safety, state-promulgated pharmacopoeia specifies, for ceftazidime antibiotic it is desirable to ceftazidime five water
The content of compound is not less than 95%, and impurity pyridine content is not higher than 0.12%, and the content of polymer is not higher than 0.3%, and other are always miscellaneous
Content is not higher than 2.0%, and its color and luster is not higher than No. 6 colors.Beta-Lactam antibiotic, such as penicillin medicine and cephalosporinses medicine
Thing, due to the less stable of parent nucleus, is susceptible to reset, decomposes and polyreaction, the polymer product being formed and allergy
Property shock have close relationship.In penicillin, averagely in 21.44 μ g/g, anaphylaxiss incidence rate is 0.2% to polymeric impurities
；Averagely in 51.24 μ g/g, anaphylaxiss incidence rate is 0.43% to polymeric impurities；Polymeric impurities average out to 76.7 μ g/g
When, allergy rate is 0.74%.Though cephalosporin anaphylaxiss are so serious not as good as penicillin, when polymer is high, equally can draw
Play human allergy's reaction.
Ceftazidime chance light, heat, water, oxidation etc. are unstable, are also easy to produce catabolite, particularly suffer from high temperature (50 DEG C of ＞)
In the case of, tend to occur degraded and polyreaction, generate ceftazidime dimer, trimer and polymer etc. polymer,
Thus leading to active constituents of medicine content to reduce, color and luster is strengthened, and polymeric impurities content raises.In addition, expired ceftazidime
Antibiotic, because the resting period is long, also usually makes active constituents of medicine content reduce, darkens, polymer content liter
High.Further, in some cases, because controlling of production process is improper, obtained ceftazidime pentahydrate, ceftazidime
Dimer, trimer and polymer etc. polymer content is especially high.And polymer content high when, easily make human body produce allergy anti-
Should.So for the high ceftazidime pentahydrate of this kind of polymeric impurities content or ceftazidime pharmaceutical preparation it is necessary to enter
One step carries out purification, ceftazidime pentahydrate crystal that obtain high-quality, that purity is high.
CN102924483B discloses a kind of ceftazidime crystalline compounds, its preparation method and its no bacterium mix powder form
Pharmaceutical composition, the preparation method of ceftazidime crystalline compounds comprises the steps：1) prepare crude product solution：By cephalo he
Pyridine crude product adds in the mixed solvent being formulated by dimethyl sulfoxide and oxolane, is stirred to dissolve, and adds activated carbon decolorizing,
Filter, obtain crude product solution, standby；2) prepare recrystallisation solvent：By acetone and ethyl acetate by volume 1-2.5: 11.5 ratio
Example prepares recrystallisation solvent, and described recrystallisation solvent volume is 6-14 times of ceftazidime crude product weight；3) crystallize：Under stirring, to
Step 1) gained crude product solution in stream plus step 2) gained recrystallisation solvent, have solid separate out；After completion of dropping, continue stirring
Mix lower Deca ethanol, separate out to there being crystal；Standing 3-6h, filter, wash with dimethyl sulfoxide, be dried, obtain described in cephalo he
Acridine compound.Compared with prior art, the invention has the advantages that：(1) ceftazidime crystal chemical combination provided by the present invention
Thing purity is high, and has preferable heat stability, and substantially non-hygroscopic；
(2) the preparation method process is simple of ceftazidime provided by the present invention, high income, repeatability is strong, is suitable for industrialization
Produce；(3) the pharmaceutical composition stability containing this ceftazidime crystalline compounds provided by the present invention is fine, thus improving
Drug safety and effectiveness, reduce the incidence rate of untoward reaction.This ceftazidime crystalline compounds uses Cu-K alpha ray
Measure the X-ray powder diffraction spectrogram obtaining as shown in Figure 3.
CN103864819A discloses a kind of ceftazidime compound and its pharmaceutical composition, the system of ceftazidime compound
Preparation Method comprises the steps：1）Preparation crude product solution：Ceftazidime crude product is added and is formulated with methanol by dimethyl sulfoxide
Mixed solvent in, control temperature 20-30 DEG C, add activated carbon decolorizing, filter, obtain ceftazidime crude product solution, standby；2）
Nucleus generating process：In the range of 20-30 DEG C, in this solution, stream adds the temperature controlling ceftazidime crude product solution under agitation
Deionized water, has muddy appearance, obtains turbid solution；3）Crystal growing process：By step 2）The turbid solution of gained is placed in super
Under sound field, control 20-30 DEG C of solution temperature, Deca chloroform thereto, separate out crystal；Close ultrasonic field, be cooled to 0-5
DEG C, filter, filter cake is washed with deionized, vacuum drying obtains described ceftazidime compound.The present invention has excellent as follows
Point：（1）Ceftazidime compound provided by the present invention has preferable heat stability, and polymer content change is little；（2）This
Bright provided ceftazidime has preferable mobility, is conducive to improving the accuracy of subpackage, and mixes with other compositions
When, be easily mixed uniformly；（3）Ceftazidime provided by the present invention has preferable bioavailability.This ceftazidime compound
The X-ray powder diffraction spectrogram being obtained using Cu-K alpha ray measurement is as shown in Figure 4.
Although above-mentioned purification process to some extent solves its purity problem, through further investigation revealed that, by
In ceftazidime during depositing, particularly under conditions of high temperature (50 DEG C of ＞), tend to occur degraded and polyreaction, with
The prolongation of resting period, its high polymer content increases, so that the risk that human body produces anaphylactic reaction is increased.
Ceftazidime is clinically typically used in the form of Ceftazidime for Injection sterilized powder.Injection head
His pyridine of spore is usually ceftazidime and pharmaceutic adjuvant mixing is aseptic subpackaged forms, and has that grain diameter is larger, and mixing is uneven, dress
Amount difference is big, and during leading to use, effective active composition ceftazidime is not easy accurate quantitative analysis.Simultaneously because ceftazidime
Purity is different so that Ceftazidime for Injection has the various problems such as color and luster, degraded, polymerization and stability, untoward reaction wind
Danger increases.
The present inventor, with existing ceftazidime crude product as raw material, through lot of experiments, has been obtained one kind and has been different from existing skill
The ceftazidime compound of the novel crystal forms of art, and by test, surprisingly find this crystalline compounds purity height, pyridine and polymerization
Thing content is low, good stability, and is difficult moisture absorption, good fluidity, substantially increases its dissolubility.Made using this crystalline compounds
Capsule dissolubility is high, impurity content is low, good stability.
Content of the invention
It is an object of the invention to provide a kind of medicine ceftazidime capsule treating Postoperative infection, described capsule
The ceftazidime crystal chemical combination that preparation method containing ceftazidime crystalline compounds provided by the present invention or the present invention is obtained
Thing.This capsule dissolubility is high, impurity content is low, good stability.
For realizing the purpose of the present invention, the present invention adopts the following technical scheme that：
A kind of medicine ceftazidime capsule treating Postoperative infection, described ceftazidime capsule, in parts by weight, by
The ceftazidime crystalline compounds of 100-200 weight portion, the Microcrystalline Cellulose of 80-100 weight portion, the crosslinked carboxylic of 8-12 weight portion
Sodium carboxymethylcellulose pyce, the micropowder silica gel composition of 2-4 weight portion；
The structural formula of described ceftazidime crystalline compounds as shown in formula I, survey by this crystalline compounds powder X-ray diffraction
Determine method measure, the X-ray powder diffraction pattern being represented with the 2 θ ± 0.2 ° angles of diffraction as shown in figure 1,
Formula（）.
Preferably, described ceftazidime capsule, in parts by weight, by the ceftazidime crystalline compounds of 150 weight portions,
The Microcrystalline Cellulose of 90 weight portions, the cross-linking sodium carboxymethyl cellulose of 9 weight portions, the micropowder silica gel composition of 3 weight portions.
Described ceftazidime capsule, is prepared from by following preparation method：
1）Feedstock treating：With vibration screen-dividing machine, ceftazidime is crossed 80 mesh sieves, standby；
2）Microcrystalline Cellulose, cross-linked carboxymethyl cellulose sodium, micropowder silica gel are crossed respectively 60 mesh sieves, standby；
3）Weigh：Carry out weighing supplementary material according to prescription；
4）Premix：Cross-linked carboxymethyl cellulose sodium of the Microcrystalline Cellulose of recipe quantity, micropowder silica gel and 1/3 recipe quantity is added to mixed
In conjunction machine, motor rotation frequency 200r/min is set, opens mixer and mix 30 minutes；
5）Always mix：Cross-linked carboxymethyl cellulose sodium of the ceftazidime of recipe quantity and 2/3 recipe quantity is added in mixer, setting
Motor rotation frequency 200r/min, opens mixer and mixes 10 minutes；It is subsequently adding pre- mixed Microcrystalline Cellulose, micropowder silica gel
And 1/3 recipe quantity cross-linked carboxymethyl cellulose sodium, arrange motor rotation frequency 150r/min, open mixer mix 20 minutes；
6）Autocapsulefillingmachine fill；
7）Packaging.
The medicine ceftazidime crystalline compounds of above-mentioned treatment Postoperative infection are obtained by following preparation method：
Take ceftazidime crude drug, in the methanol of addition uniform temperature, the mixed solvent A of dimethylformamide, obtain solution；So
Apply stationary magnetic field in the horizontal direction of the liquid level of resulting solution afterwards, and to Deca in solution under conditions of this stationary magnetic field
Acetone, ethyl acetate, the mixed solvent B of ether；After being added dropwise to complete, stand 4 hours, filter, filter cake washing with alcohol, vacuum is done
Dry 3 hours, obtain described ceftazidime crystalline compounds.
Described ceftazidime crude drug can be the head as disclosed in CN102391289A for the method using prior art
Ceftazidime pentahydrate or commercially available ceftazidime pentahydrate raw material that the synthetic method of his pyridine of spore prepares
Medicine.
In above-mentioned preparation method, wherein, described uniform temperature is 35-45 DEG C.The volume of described mixed solvent A（ml）For head
His pyridine weight of spore（g/ml）6-8 times, methanol and dimethylformamide volume ratio are 1:2.5.Described magnetic field intensity is 0.8T-
1.5T.The volume of described mixed solvent B（ml）For ceftazidime weight（g/ml）8-10 times, acetone, ethyl acetate and ether
Volume ratio is 2:3:5.
Compared with prior art, the invention has the advantages that：
（1）Not only purity is high for ceftazidime crystalline compounds provided by the present invention, and pyridine and polymer content are low, stability
Good, and it is difficult moisture absorption, and mobility, dissolubility etc. are substantially better than prior art；
（2）The preparation method process is simple of ceftazidime provided by the present invention, high income, repeatability is strong, is suitable for industrialization
Produce；
（3）Capsule dissolubility containing this ceftazidime crystalline compounds provided by the present invention is high, impurity content is low, stability
Good.
Brief description
The X-ray powder diffraction figure of the ceftazidime crystalline compounds that Fig. 1 provides for the present invention；
Fig. 2 is the heat analysis collection of illustrative plates of the ceftazidime crystalline compounds shown in Fig. 1；
Fig. 3 is the X-ray powder diffraction collection of the ceftazidime crystallization of patent CN102924483B embodiment preparation；
Fig. 4 is the X-ray powder diffraction collection of the ceftazidime crystallization of patent CN103864819A embodiment preparation.
Specific embodiment
With embodiment, technical scheme is described in detail below, it will help the technical side to the present invention
The advantage of case, effect have and further understand, embodiment does not limit protection scope of the present invention, protection scope of the present invention by
Claim is determining.
The preparation of embodiment 1 ceftazidime crystalline compounds
Take ceftazidime crude drug, the volume adding 35 DEG C is the methanol of 6 times of ceftazidime weight, the mixing of dimethylformamide
In solvent orange 2 A, methanol and dimethylformamide volume ratio are 1:2.5, obtain solution；Then in the level side of the liquid level of resulting solution
Upwards apply magnetic field intensity be 0.8T stationary magnetic field, and under conditions of this stationary magnetic field to Deca volume in solution be cephalo
He is 8 times of acetone of pyridine weight, ethyl acetate, the mixed solvent B of ether, and the volume ratio of acetone, ethyl acetate and ether is 2:3:5；
After being added dropwise to complete, stand 4 hours, filter, filter cake washing with alcohol, be vacuum dried 3 hours, obtain described ceftazidime crystal
Compound.
Measured with powder X-ray diffraction algoscopy, the X-ray powder diffraction collection being represented with the 2 θ ± 0.2 ° angles of diffraction is such as
Shown in Fig. 1, at 3.1 °, 4.0 °, 6.0 °, 6.7 °, 9.5 °, 14.1 °, 22.1 °, 24.5 °, 36.1 °, 37.9 °, show feature
Diffraction maximum.
Measuring moisture using Ka Shi aquametry is 14.13 wt%, substantially identical with theoretical value.
Measured using thermogravimetric analysiss, result is as shown in Fig. 2 crystal water content is 14.15wt%, substantially identical with theoretical value.
The preparation of embodiment 2 ceftazidime crystalline compounds
Take ceftazidime crude drug, the volume adding 40 DEG C is the methanol of 7 times of ceftazidime weight, the mixing of dimethylformamide
In solvent orange 2 A, methanol and dimethylformamide volume ratio are 1:2.5, obtain solution；Then in the level side of the liquid level of resulting solution
Upwards apply magnetic field intensity be 1.1T stationary magnetic field, and under conditions of this stationary magnetic field to Deca volume in solution be cephalo
He is 9 times of acetone of pyridine weight, ethyl acetate, the mixed solvent B of ether, and the volume ratio of acetone, ethyl acetate and ether is 2:3:5；
After being added dropwise to complete, stand 4 hours, filter, filter cake washing with alcohol, be vacuum dried 3 hours, obtain described ceftazidime crystal
Compound.
Measured with powder X-ray diffraction algoscopy, same with the X-ray powder diffraction collection that the 2 θ ± 0.2 ° angles of diffraction represent
Embodiment 1.
The preparation of embodiment 3 ceftazidime crystalline compounds
Take ceftazidime crude drug, the volume adding 45 DEG C is the methanol of 8 times of ceftazidime weight, the mixing of dimethylformamide
In solvent orange 2 A, methanol and dimethylformamide volume ratio are 1:2.5, obtain solution；Then in the level side of the liquid level of resulting solution
Upwards apply magnetic field intensity be 1.5T stationary magnetic field, and under conditions of this stationary magnetic field to Deca volume in solution be cephalo
He is 10 times of acetone of pyridine weight, ethyl acetate, the mixed solvent B of ether, and the volume ratio of acetone, ethyl acetate and ether is 2:3:5；
After being added dropwise to complete, stand 4 hours, filter, filter cake washing with alcohol, be vacuum dried 3 hours, obtain described ceftazidime crystal
Compound.
Measured with powder X-ray diffraction algoscopy, same with the X-ray powder diffraction collection that the 2 θ ± 0.2 ° angles of diffraction represent
Embodiment 1.
The preparation of embodiment 4 ceftazidime crystalline compounds
Take ceftazidime crude drug, the volume adding 35 DEG C is the methanol of 7 times of ceftazidime weight, the mixing of dimethylformamide
In solvent orange 2 A, methanol and dimethylformamide volume ratio are 1:2.5, obtain solution；Then in the level side of the liquid level of resulting solution
Upwards apply magnetic field intensity be 1.1T stationary magnetic field, and under conditions of this stationary magnetic field to Deca volume in solution be cephalo
He is 10 times of acetone of pyridine weight, ethyl acetate, the mixed solvent B of ether, and the volume ratio of acetone, ethyl acetate and ether is 2:3:5；
After being added dropwise to complete, stand 4 hours, filter, filter cake washing with alcohol, be vacuum dried 3 hours, obtain described ceftazidime crystal
Compound.
Measured with powder X-ray diffraction algoscopy, same with the X-ray powder diffraction collection that the 2 θ ± 0.2 ° angles of diffraction represent
Embodiment 1.
The preparation of embodiment 5 ceftazidime crystalline compounds
Take ceftazidime crude drug, the volume adding 45 DEG C is the methanol of 6 times of ceftazidime weight, the mixing of dimethylformamide
In solvent orange 2 A, methanol and dimethylformamide volume ratio are 1:2.5, obtain solution；Then in the level side of the liquid level of resulting solution
Upwards apply magnetic field intensity be 0.8T stationary magnetic field, and under conditions of this stationary magnetic field to Deca volume in solution be cephalo
He is 8 times of acetone of pyridine weight, ethyl acetate, the mixed solvent B of ether, and the volume ratio of acetone, ethyl acetate and ether is 2:3:5；
After being added dropwise to complete, stand 4 hours, filter, filter cake washing with alcohol, be vacuum dried 3 hours, obtain described ceftazidime crystal
Compound.
Measured with powder X-ray diffraction algoscopy, same with the X-ray powder diffraction collection that the 2 θ ± 0.2 ° angles of diffraction represent
Embodiment 1.
【Example of formulations 1】Ceftazidime capsule
In parts by weight, prescription composition is as follows：100 parts of ceftazidime, 80 parts of Microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose 8
Part, 2 parts of micropowder silica gel.
Ceftazidime is the ceftazidime crystalline compounds that the embodiment of the present invention 1 is obtained.
Preparation method：
1）Feedstock treating：With vibration screen-dividing machine, ceftazidime is crossed 80 mesh sieves, standby；
2）Microcrystalline Cellulose, cross-linked carboxymethyl cellulose sodium, micropowder silica gel are crossed respectively 60 mesh sieves, standby；
3）Weigh：Carry out weighing supplementary material according to prescription；
4）Premix：Cross-linked carboxymethyl cellulose sodium of the Microcrystalline Cellulose of recipe quantity, micropowder silica gel and 1/3 recipe quantity is added to mixed
In conjunction machine, motor rotation frequency 200r/min is set, opens mixer and mix 30 minutes；
5）Always mix：Cross-linked carboxymethyl cellulose sodium of the ceftazidime of recipe quantity and 2/3 recipe quantity is added in mixer, setting
Motor rotation frequency 200r/min, opens mixer and mixes 10 minutes；It is subsequently adding pre- mixed Microcrystalline Cellulose, micropowder silica gel
And 1/3 recipe quantity cross-linked carboxymethyl cellulose sodium, arrange motor rotation frequency 150r/min, open mixer mix 20 minutes；
6）Autocapsulefillingmachine fill；
7）Packaging.
【Example of formulations 2】Ceftazidime capsule
In parts by weight, prescription composition is as follows：100 parts of ceftazidime, 90 parts of Microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose 12
Part, 2 parts of micropowder silica gel.
Preparation method：With example of formulations 1, except that ceftazidime used is the cephalo prepared by embodiment 2
His pyridine crystalline compounds.
【Example of formulations 3】Ceftazidime capsule
In parts by weight, prescription composition is as follows：150 parts of ceftazidime, 90 parts of Microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose 9
Part, 3 parts of micropowder silica gel.
Preparation method：With example of formulations 1, except that ceftazidime used is the cephalo prepared by embodiment 3
His pyridine crystalline compounds.
【Example of formulations 4】Ceftazidime capsule
In parts by weight, prescription composition is as follows：200 parts of ceftazidime, 80 parts of Microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose 12
Part, 2 parts of micropowder silica gel.
Preparation method：With example of formulations 1, except that ceftazidime used is the cephalo prepared by embodiment 4
His pyridine crystalline compounds.
【Example of formulations 5】Ceftazidime capsule
In parts by weight, prescription composition is as follows：200 parts of ceftazidime, 100 parts of Microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose
12 parts, 4 parts of micropowder silica gel.
Preparation method：With example of formulations 1, except that ceftazidime used is the cephalo prepared by embodiment 5
His pyridine crystalline compounds.
Trial target 1：Ceftazidime crystalline compounds prepared by the embodiment of the present invention 1；
Trial target 2：Ceftazidime crystalline compounds prepared by the embodiment of the present invention 3；
Reference substance 1：Method according to CN102924483B embodiment 1 is obtained ceftazidime crystalline compounds；
Reference substance 2：Method according to CN103864819A embodiment 1 is obtained ceftazidime compound；
Reference substance 3：Method according to CN105560194A embodiment 1 is obtained ceftazidime；
Reference substance 4：Method according to CN105585582A embodiment 1 is obtained ceftazidime.
Experimental example 1：Heat stabilization test
It is, in the environment of 75%, temperature is 60 DEG C, to have according in CN105560194A that each sample is respectively exposed to relative humidity
Pass material, impurity pyridine, the detection method of polymer detect to items, the results are shown in Table 1：
Table 1 heat stabilization test result
Pyridine is two class noxious substances, and pyridine can stimulate human eye, skin and respiratory tract, to human central nervous system, liver,
Kidney, gastrointestinal all have an impact, and consciousness of personality can be caused to reduce.If pyridine residual quantity is high, more serious impact can be produced on human body.Logical
Cross the security test to ceftazidime medicine, pyridine residual limit of safety in ceftazidime medicine not can exceed that
0.12%.Contain pyridine groups due in ceftazidime structure, medicine, in placement process, can gradually decompose impurity pyridine and go out
Come, particularly the ceftazidime of stability difference, in placement process, pyridine residual quantity can increase comparatively fast, and this has relatively to human body
Big harm.
The height of drug quality is directly connected to the health of millions upon millions of working people's bodies, is also related to China's economic construction
Effect, the consolidation of national defence and nationality flourishing；It has been far from the thing of medical industry enterprise scope itself, but entirely
The national, major issue in the world.Those skilled in the art all clearly know, in the present age that pharmaceutical technology is flourishing, drug safety standard quilt
Constantly lifted, the purity also more and more higher of prepared medicine, be effectively reduced impurity content, even the several percentage of zero point
Point it is also possible to effectively reduce the generation of untoward reaction, therefore impurity content to drug quality and people's drug safety to closing weight
Will.Medicine needs to store and transport just can cure the sickness to save the patient from production to the process of circulation, therefore, medicine in storage and transportation
Quality be particularly important, stability is the key determining drug quality quality, in medicine storage and transportation, stable
Property bad, impurity change directly affect greatly people's drug safety.
As can be seen from the above table, the relevant material of ceftazidime crystalline compounds of present invention offer, pyridine, polymer etc.
Content is all very low, and heat stability is significantly better than the ceftazidime being obtained after purification using the method for prior art, effectively
Improve the stability of drug safety and storage, reduce the generation of untoward reaction.
Above-mentioned test is also carried out to the ceftazidime crystalline compounds of other embodiments of the present invention, its result phase obtaining
Seemingly.
Experimental example 2：Fluidity test
This experimental example evaluates the mobility of sample by the angle of repose of determination sample, and concrete grammar is as follows：Take sample particle, from
Flow in fixing little funnel in the surface plate of circle, until obtaining highest cone, measure cone height H and radius R,
Calculate α angle of repose by tan α=H/R, the results are shown in Table 2, angle of repose is bigger, mobility is poorer.
Table 2 fluidity test result
As known from Table 2, compared with ceftazidime of the prior art, the ceftazidime compound flow that the present invention provides is notable
Improve, be conducive to improving the accuracy of subpackage, and be easily mixed when mixing with other compositions uniformly.
Experimental example 3：Dissolubility test
Add appropriate distilled water in the low capacity bottle with constant temperature jacket, add ceftazidime at 20 DEG C to not re-dissolved
Till, start magnetic stirrer, continuously stirred under constant temperature, system is in the state of two-phase coexistent all the time in experimentation, 70
In the liquid phase of system after minute, the concentration of ceftazidime is the dissolubility at a temperature of this.It is sampled after 2 hours analyzing, take
The close meansigma methodss of adjacent two times result as measured value of experiment, before sampling, in order that solid-liquid is sufficiently separated, stop stirring after,
Not molten ceftazidime is deposited to the bottom of low capacity bottle, extracts a small amount of upper clear supernate with syringe, with 0.45 micron of filter
Filter, take sample from filtrate, measure the content of ceftazidime by HPLC（Concentration（mg/ml））.The results are shown in Table 3.
Under table 3 room temperature, ceftazidime crystal compound of the present invention and the water solublity of prior art crystal formation contrast
From table 3 it can be seen that the water solublity of the ceftazidime crystal compound of present invention offer is compared with prior art, have aobvious
Write and improve.
Experimental example 4：Wettability test
Each sample opening is put in clean culture dish, spreads out into≤thick the thin layer of 5mm, each two parts, be respectively put into constant humidity hermetic container
In, place 10 days under conditions of relative humidity 75% and 92.5% at 25 DEG C, sampled in the 5th day and the 10th day, pass through
The moisture of loss on drying experiment measurement each sample, result of the test was compared with 0 day, and experimental result is shown in Table 4.
Table 4 hygroscopicity test results
As can be seen from the above table, the ceftazidime crystalline compounds that the present invention provides are substantially non-hygroscopic under high humidity conditions, its
Stability under high humidity environment is substantially better than the ceftazidime obtaining using the purification process process of prior art.
Experimental example 5：Prescription screening is tested（Using capsule preparation method thereof of the present invention preparation）
Table 5a prescription screening experimental result
Table 5b prescription screening experimental result
As can be seen from the above table, ceftazidime capsule of the present invention（Prescription 11）Not only mobility, dissolution are good, and are polymerized
Thing, always miscellaneous content significantly reduce.
Experimental example 6：Preparation influence factor tests
Formulation test product 1：Ceftazidime capsule prepared by invention formulation embodiment 1.
Formulation test product 2：Ceftazidime capsule prepared by invention formulation embodiment 3.
By formulation test product simulation listing packaging, in 60 DEG C of high temperature, illumination 4500Lx, high humidity（RH90%±5%）Under the conditions of
Place 10 days, detected by stability high spot reviews project, compare with 0 day sample, the results are shown in Table 6.
Table 6 preparation influence factor's result of the test
Found by result above, the capsule dissolubility containing this ceftazidime crystalline compounds prepared by the present invention is high, impurity
Content is low, good stability.
Above-mentioned test is also carried out to the ceftazidime capsule of present invention other example of formulations, its result phase obtaining
Seemingly.
Claims (3)
1. a kind of medicine ceftazidime capsule treating Postoperative infection it is characterised in that：In parts by weight, by 100-200
The ceftazidime crystalline compounds of weight portion, the Microcrystalline Cellulose of 80-100 weight portion, the cross-linked carboxymethyl fibre of 8-12 weight portion
The plain sodium of dimension, the micropowder silica gel composition of 2-4 weight portion；
Above-mentioned ceftazidime crystalline compounds are measured with powder X-ray diffraction algoscopy, are penetrated with the X that the 2 θ ± 0.2 ° angles of diffraction represent
Line powder diffraction spectrum is as shown in Figure 1.
2. according to claim 1 treatment Postoperative infection medicine ceftazidime capsule it is characterised in that：With weight
Part meter, by the ceftazidime of 150 weight portions, the Microcrystalline Cellulose of 90 weight portions, the cross-linking sodium carboxymethyl cellulose of 9 weight portions, 3
The micropowder silica gel composition of weight portion.
3. according to claim 1 and 2 treatment Postoperative infection medicine ceftazidime capsule it is characterised in that by
Following preparation method is prepared from：
1）Feedstock treating：With vibration screen-dividing machine, ceftazidime is crossed 80 mesh sieves, standby；
2）Microcrystalline Cellulose, cross-linked carboxymethyl cellulose sodium, micropowder silica gel are crossed respectively 60 mesh sieves, standby；
3）Weigh：Carry out weighing supplementary material according to prescription；
4）Premix：Cross-linked carboxymethyl cellulose sodium of the Microcrystalline Cellulose of recipe quantity, micropowder silica gel and 1/3 recipe quantity is added to mixed
In conjunction machine, motor rotation frequency 200r/min is set, opens mixer and mix 30 minutes；
5）Always mix：Cross-linked carboxymethyl cellulose sodium of the ceftazidime of recipe quantity and 2/3 recipe quantity is added in mixer, setting
Motor rotation frequency 200r/min, opens mixer and mixes 10 minutes；It is subsequently adding pre- mixed Microcrystalline Cellulose, micropowder silica gel
And 1/3 recipe quantity cross-linked carboxymethyl cellulose sodium, arrange motor rotation frequency 150r/min, open mixer mix 20 minutes；
6）Autocapsulefillingmachine fill；
7）Packaging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610845670.2A CN106420658A (en) | 2016-09-23 | 2016-09-23 | Ceftazidime capsule for treating surgical infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610845670.2A CN106420658A (en) | 2016-09-23 | 2016-09-23 | Ceftazidime capsule for treating surgical infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106420658A true CN106420658A (en) | 2017-02-22 |
Family
ID=58166080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610845670.2A Withdrawn CN106420658A (en) | 2016-09-23 | 2016-09-23 | Ceftazidime capsule for treating surgical infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420658A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4329453A (en) * | 1979-10-02 | 1982-05-11 | Glaxo Group Limited | Cephalosporin antibiotic |
| US4624948A (en) * | 1983-04-16 | 1986-11-25 | Hoechst Aktiengesellschaft | Crystalline modification of ceftazidim |
| CN1441668A (en) * | 2000-06-21 | 2003-09-10 | 卡比斯特制药公司 | Compositions and methods to improve oral absorption of antimicrobial agents |
| CN1939264A (en) * | 2005-09-26 | 2007-04-04 | 刘凤鸣 | Oral preparation containing ceftazidime and its making method |
-
2016
- 2016-09-23 CN CN201610845670.2A patent/CN106420658A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4329453A (en) * | 1979-10-02 | 1982-05-11 | Glaxo Group Limited | Cephalosporin antibiotic |
| US4624948A (en) * | 1983-04-16 | 1986-11-25 | Hoechst Aktiengesellschaft | Crystalline modification of ceftazidim |
| CN1441668A (en) * | 2000-06-21 | 2003-09-10 | 卡比斯特制药公司 | Compositions and methods to improve oral absorption of antimicrobial agents |
| CN1939264A (en) * | 2005-09-26 | 2007-04-04 | 刘凤鸣 | Oral preparation containing ceftazidime and its making method |
Non-Patent Citations (1)
| Title |
|---|
| 倪坤仪，等: "《药物分析化学》", 31 August 2001, 南京：东南大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118290502A (en) | Erigeron breviscapus-huperzine A co-amorphous substance with synergistic antioxidation effect and preparation method thereof | |
| CN102276630A (en) | Cefminox sodium crystalline compound and composition powder injection thereof | |
| WO2020001406A1 (en) | Crystal habit of quinoline derivative and preparation method for crystalline powder thereof | |
| CN106420658A (en) | Ceftazidime capsule for treating surgical infection | |
| AU2012389714B2 (en) | Cocrystal of piperacillin sodium and sulbactam sodium and preparation method thereof, as well as pharmaceutical compositions containing same and uses thereof | |
| CN106432279A (en) | Method for preparing medicine ceftriaxone sodium crystal compound for treating surgical infection | |
| CN106432274A (en) | Crystalline compound of drug ceftriaxone sodium for treating surgical operation infections | |
| CN106432281A (en) | Preparation method of pharmaceutical ceftazidime crystal compound for treating surgical infection | |
| CN106432278A (en) | Crystalline compound of drug ceftriaxone sodium for treating surgical operation infections | |
| CN106397455B (en) | A kind of anti-infectives Ceftibuten crystalline compounds and combinations thereof | |
| CN104844624B (en) | A kind of cefoperazone sodium sulbactam sodium eutectic and composition and method of making the same | |
| CN106397458A (en) | Ceftazidime crystal compound as drug for treating infection during surgical operation | |
| CN106420619A (en) | Drug ceftazidime dry suspension for treating surgery infection | |
| CN106432280A (en) | Medicine ceftazidime crystalline compound for treating surgical operation infection | |
| CN106432282A (en) | Preparation method of ceftazidime crystal compound for treating surgical infection | |
| CN106420760A (en) | Ceftibuten pharmaceutical composition for treating surgical infection | |
| CN106432271A (en) | Pharmaceutical ceftibuten crystal compound for treating surgical infection | |
| CN106432272A (en) | Method for preparing drug ceftibuten crystal compound for treating surgical operation infection | |
| CN106432275A (en) | Method for preparing crystalline ceftriaxone sodium compound as drug for treating surgical infection | |
| CN106317081B (en) | A kind of anti-infectives cefotaxime crystalline compounds and its pharmaceutical composition | |
| CN105640895A (en) | Cefadroxil granular preparation and preparation method thereof | |
| CN106432270A (en) | Method for preparing medicine ceftibuten crystal compound for treating surgical infection | |
| CN106420617A (en) | Medicine ceftibuten powder injection for treating surgical infection | |
| CN106397457A (en) | Drug ceftibuten crystal compound for treating surgical operation infection | |
| CN106397454B (en) | A kind of anti-infectives Ceftibuten crystal-form compound and combinations thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170222 |